Clinical trials: Vehicle, completed
Atopic Dermatitis, Eczema
A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03089229
- Testing
- HAT01H Cream, Vehicle Cream
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Haus Bioceuticals
HIV Infections, Tuberculosis
Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years of age.
- Trial name
- NCT00802802
- Testing
- Efavirenz (EFV), Rifampin-containing anti-TB therapy
- Where
- 7 sites in India, South Africa and 2 more
- Volunteers
- 67 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Submental Fat
Efficacy and Safety of RZL-012 on Submental Fat Reduction
A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo…
- Trial name
- NCT04867434
- Testing
- RZL-012
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Raziel Therapeutics Ltd.
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03839693
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eirion Therapeutics Inc.
Schizophrenia
Oxytocin as Adjunctive Treatment of Schizophrenia
The focus of the current project is to advance our understanding of the effects of oxytocin (OT) on components of social cognition in schizophrenia (SCZ).
- Trial name
- NCT01568528
- Testing
- Oxytocin, Control
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Emory University
Critical Limb Ischemia
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
This study is designed to evaluate the efficacy and safety of ixmyelocel-T, a patient-specific expanded multicellular therapy, for the treatment of patients with critical limb ischemia (CLI).
- Trial name
- REVIVE (NCT01483898)
- Testing
- Ixmyelocel-T
- Where
- 86 sites in United States
- Volunteers
- 41 people
- Sponsor
- Vericel Corporation
Dermatitis, Atopic
Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis
This study is being conducted to evaluate the efficacy and safety of 3 different application rates of topically applied Crisaborole ointment 2% over vehicle in adults with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT03868098
- Testing
- Crisaborole 2%
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Innovaderm Research Inc.
Distal, Subungual Onychomycosis
Study of Different Doses of a Novel Treatment for Onychomycosis
The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.
- Trial name
- NCT00679965
- Testing
- AN2690, 2.5%, AN2690, 5%, AN2690, 7.5%
- Where
- 9 sites in Mexico
- Volunteers
- 159 people
- Sponsor
- Pfizer
Psoriasis
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers.
- Trial name
- NCT03469336
- Testing
- PF-06763809, Vehicle, Calcipotriene/calcipotriol
- Where
- 2 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Pfizer
Dry Eye Disease
Study Evaluating the Safety and Efficacy of AR-15512
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED).
- Trial name
- COMET-2 (NCT05285644)
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 23 sites in United States
- Volunteers
- 465 people
- Sponsor
- Aerie Pharmaceuticals
Diarrhea
Sanitation Demand Creation in Peri-Urban Slums of Lusaka, Zambia
This intervention will experimentally test the hypothesis that sanitation can be improved in a peri-urban setting using state-of-the-art behaviour change communications.
- Trial name
- SanDem (NCT03174015)
- Testing
- Bauleni Secret
- Where
- Zambia
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Molluscum Contagiosum
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
- Trial name
- NCT03436615
- Testing
- SB206 4%, SB206 8%, SB206 12%
- Where
- 18 sites in United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.
Acne Vulgaris
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761784
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 424 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Presbyopia
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia.
- Trial name
- OPSIS (NCT05665387)
- Testing
- 0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution
- Where
- 12 sites in United States
- Volunteers
- 79 people
- Sponsor
- Santen Inc.
Acne Vulgaris
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of…
- Trial name
- NCT02661958
- Testing
- S6G5T-3, S6G5T-1, S6G5T-5
- Where
- 34 sites in United States
- Volunteers
- 726 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Plaque Psoriasis
Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis
To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of plaque psoriasis
- Trial name
- NCT03005964
- Testing
- AM001 Cream, 7.5%, Vehicle Cream
- Where
- 2 sites in Dominican Republic
- Volunteers
- 74 people
- Sponsor
- AmDerma
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution
The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9778 ophthalmic solution (eye drops) administered for 7 days in adults.
- Trial name
- NCT04284514
- Testing
- AKB-9778 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Aerpio Therapeutics
Actinic Keratosis
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
- Trial name
- NCT01962987
- Testing
- Diclofenac sodium
- Where
- 31 sites in United States
- Volunteers
- 476 people
- Sponsor
- Actavis Inc.
Herpes Simplex
A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children
Limited data are available on valaciclovir use in children and valaciclovir is not currently approved for use in pediatrics. The marketed formulation of valaciclovir is not ideal for use in pre-adolescent patients who may have…
- Trial name
- NCT00297206
- Testing
- Valaciclovir
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.